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The human (h) TXA2  receptor (TP), a G protein-coupled receptor, exists as two isoforms, TPα and TPβ, which arise 
by alternative mRNA splicing and differ exclusively in their carboxyl terminal cytoplasmic regions. In this study, a 
reverse transcriptase - polymerase chain reaction (RT-PCR) based strategy was developed to examine the expression 
of the TPs in tissues of physiologic relevance to TXA2.  Although most of the  17 different cell / tissue types 
examined expressed  both TP isoforms, the liver hepatoblastoma HepG2 cell line was found to exclusively express 
TPα mRNA.  In most cell types, TPα mRNA  predominated over TPβ  mRNA. Moreover, although the levels of TPα  
mRNA expression were similar in most of the cell / tissue types examined, extensive differences in the levels of TPβ 
mRNA were observed.  Consequently, the relative expression of TPα  : TPβ mRNA varied considerably due to 
extensive differences in TPβ mRNA expression.  Most strikingly,  primary HUVEC’s were found to express: (i) low 
levels of TPβ and  (ii) approximately 6- fold greater levels of TPα  than TPβ .  These data were confirmed in the 
spontaneously transformed HUVEC derived ECV304 cell line.  Expression of TP mRNAs in the various tissue / 








The prostanoid thromboxane A2 (TXA2), mainly synthesised in platelets, induces a variety of cellular responses 
including platelet shape change and aggregation, constriction of bronchial and vascular smooth muscle (VSM) cells, 
stimulation of mitogenesis and / or hypertrophic responses in VSM (1 - 5). TXA2 mediates its actions through 
interaction with the shared endoperoxide prostaglandin (PG)H2 / TXA2 receptor (termed TP; 6), a member of the 
rhodopsin like G protein coupled receptor (GPCR) family.  Imbalances in the levels of TXA2 or in its specific TXA2 
synthase or its receptor (TP) have been implicated as mediators  in a number of disease states including myocardial 
infarction (7 - 9), atherosclerosis (10), angina (9, 7), pregnancy induced hypertension (11),  ureteral obstruction (12), 
lupus nephritis (13), dysmenorrhea and uterine ischemia (14), endometrial cancer (15) and bronchial asthma (16). In 
addition, U46619, a TP agonist has been  reported to induce apoptotic cell death of immature thymocytes (17) 
implying that TXA2 may play a role in modulation of immune responses (18).   
 Early pharmacological and biochemical evidence indicated both inter and intra-species variations of TPs 
(19 - 22 ).  Moreover,  the selective TP antagonist GR32191 could distinguish between two forms of the receptor in 
human platelets; one linked to phospholipase C activation, resulting in platelet aggregation and granule secretion and 
a second linked to calcium mobilization, mediating platelet shape change (2). The cDNA for the human TP was 
initially cloned from placenta and the platelet like MEG-01 cell line (23) and since then cDNAs for TP receptors 
from a number of species have been cloned including TPs from mouse (24), rat (25,26) and bovine (27) sources. All 
TPs are predicted to share similar 7 transmembrane, α helical domain arrangements typical of members of the GPCR 
superfamily.  Despite the evidence for receptor heterogeneity, genomic cloning of the human TP gene confirmed the 
existence of a single gene, located on chromosome 19p13.3 (28). The gene consists of 3 exons and 2 introns and has 
2 putative promoters; DNA sequence analysis indicates polymorphism, including polymorphism within the putative 
promoter 2 (29).  In 1994, Raychowdhury et al., (30) isolated a cDNA encoding a second isoform of the TP from a 
human umbilical vein endothelial cell (HUVEC) cDNA library.  The endothelial receptor, termed TPβ, and the 
platelet/placental TP, termed TPα, are encoded by the same gene but arise by a novel differential splicing event.  The 
two receptors are identical for the first 328 amino acids but differ in their C-terminal terminal cytoplasmic tails.  
Polymerase chain reaction (PCR) experiments indicated that HUVECs express TPβ only (30) whereas platelets were 
reported to express both TPα and TPβ isoforms (31). 
 Both receptor isoforms have been shown to be regulated both in vitro  and in vivo  by phosphorylation 
(32,33).  Direct functional coupling of TPα to Gq and G11 in response to the TXA2 mimetic U46619 and the 
isoprostane 8-epi prostaglandin F2α has been demonstrated in vivo (34).    Moreover, in stably transfected Chinese 
hamster ovary cells, Hirata et al., (31) reported that the individual receptors may activate different intracellular 
signalling pathways.  Whilst showing similar phospholipase C activation, each receptor oppositely regulate adenylyl 
cyclase activity, with TPα activating it and TPβ inhibiting it.  None the less, despite these studies, the physiologic 
significance of the existence of 2 receptors for TXA2 is presently unclear but it is possible that each receptor isoform 
may be involved in mediating specific functions among the diversity of those attributed to the autocoid TXA2.  To 
date, no detailed study has been undertaken to analyse the relative expression of the TPα or TPβ isoforms in cells or 
tissues of relevance to TXA2 biology.  Whereas Northern blot analyses have confirmed the existence of TP mRNA in 
human MEG-01 cells, placental and lung tissue (23), in human erythroleukemic (HEL) cells (35,29)  and in mouse 
thymus, lung, spleen, ileum brain and kidney (36), the probes utilised in these studies did not discriminate between 
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expression of the α or β isoforms.  Similarly, at the protein level, TP selective radioligands currently available, such 
as [3H]SQ29,549 (30,37) or [3H]S-145 (31) do not discriminate between either receptor isoform and sufficiently 
sensitive receptor specific antibodies that will allow for detection of low amounts of TP expressed on cell 
membranes are not currently available.  As a necessary prelude to studies which may elucidate the possible 
differential physiologic roles of the TPs, it is necessary to establish the expression and tissue distribution of the 
individual TP isoforms. Hence, in this study, a semi quantitative reverse-transcriptase PCR (RT-PCR) approach has 
been developed that allows for the identification of and the assessment of relative expression and abundance of the 
mRNAs for the TPα and TPβ isoforms from different tissue and cell types.  Where possible, TP receptor expression 
was validated by radioligand binding studies using the highly selective TP antagonist SQ29,548.   This study will 
provide a starting foundation for elucidating the roles of TP isoforms in physiologic and pathophysiologic states. 
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Materials and Methods 
Materials. Ultraspec total RNA isolation system was purchased from Biotecx Laboratories (Houston, TX). All 
oligonucleotides were synthesised by Genosys Biotechnologies (Cambridgeshire, UK). Mouse moloney leukemia 
virus (MMLV) reverse transcriptase (RT), ribonuclease inhibitor RNasin®, Klenow fragment, RQ DNase I and 
deoxynucleotides were purchased from Promega. Random hexamers were purchased from Life Technologies Inc. 
Taq DNA polymerase, T4 DNA ligase, calf intestinal alkaline phosphatase and restriction endonucleases were 
purchased from Boehringer Mannheim. Sequenase Version 2.0 DNA sequencing kit was purchased from U.S. 
Biochemical Corp. Foetal bovine serum (FBS) was purchased from PAA laboratories Ltd., (Kingston Upon Thames, 
UK.). Dulbecco’s minimal essential medium, RPMI 1640 and minimal essential medium were purchased from 
HyClone Europe (Northumberland, UK). Endothelial growth medium  (EGM) and supplements were purchased from 
BioWhittaker Inc., (Walkerville, MD, U.S.A.). All human tissue RNA samples were purchased from Clontech. The 
Escherichia coli (E.coli) cloning vector pBluescript II SK(-) was purchased from Stratagene.  
 
Culture of Primary and Immortalised Cells: 
Primary (1o) human umbilical vein endothelial (HUVEC) cells and first trimester trophoblast cell lines, namely ED-
27, ED-31, ED-77 and Tm-1, derived from 4 individual donors were obtained from Professor Desmond Fitzgerald, 
Royal College of Surgeons, Dublin, Ireland.  The following immortalised human cell lines were purchased from the 
American Type Culture Collection (ATCC): Human erythroleukemia (HEL) 92.1.7 cells;  hepatoblastoma (Hep) G2 
cells; ECV304 cells.  The foetal and adult aortic vascular smooth muscle (VSM) cell lines VLTR and ALTR and the 
uterine smooth muscle cell (SMC) line ULTR, described by Perez-Reyes et al., (38), were obtained from J. K. 
McDougall, Dept. Pathology, University of Washington, Seattle, USA. 
All cells were maintained at 5% CO2 in an incubator at 37oC and were cultured using standard conditions, essentially 
as recommended by the suppliers.  Briefly, the megakaryocytic HEL cell line were routinely cultured in RPMI 1640, 
10% FBS. Immortalised VSM cell lines, VLTR, ALTR; the uterine SMC cells, ULTR; the 1o trophoblast cell lines 
ED-27, ED-31, ED-77 and Tm-1, were routinely grown in Dulbecco’s minimal essential medium, 10% FBS. The 
liver-derived cell line, HepG2 cells were cultured in Eagle’s minimal essential medium, 10% FBS. The 
spontaneously transformed HUVEC-derived cell line, ECV304 was cultured in medium 199, 10% FBS whereas the 
1o HUVEC cells was grown in EGM supplemented with 10 ng ml-1 human epidermal growth factor, 0.5 µg ml-1 
hydrocortisone, 50 µg ml-1 gentamicin sulphate, 50 µg ml-1 amphotericin B, 12 µg ml-1 bovine brain extract, 2% 
FBS. 
 
RNA  Preparation. 
Total RNA from foetal and adult brain tissue, thymus, small intestine and liver were purchased from Clontech.  Total 
RNA was isolated from placental tissue and all cell lines using the Ultraspec® RNA isolation procedure, essentially 
as described by the supplier. RNA integrity was assessed by electrophoresis on 1.1% 
agarose/formaldehyde/formamide gels (39).  To ensure that the RNA samples prepared using the Ultraspec® method 
were free from any potential contaminating  DNA, aliquots (25µg) of total RNA were treated with 6.25U RQ DNase 
I in the presence of 40U RNasin® ribonuclease inhibitor, 50mM Tris-HCl, pH 7.5., 10mM MgCl2 for 15 minutes at 
37oC in a total volume of 50µl. Reactions were terminated by the addition of 2.5µl 0.5M EDTA, pH 8.0. 
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Phenol:chloroform extraction and precipitation of the RNA were performed by standard methodology (39). The 
lyophilised RNA pellet was resuspended in 20µl diethyl pyrocarbonate (depc) treated H20.   
  
Reverse Transcription and Polymerase Chain Reaction (RT-PCR) 
DNase I treated total RNA from immortalised cell lines and total RNA extracted from human tissue were converted 
to first strand (Io) cDNA with MMLV RT. Briefly, 1.4µg of total RNA was denatured for 10 minutes at 70oC in the 
presence of random hexamers (100µM), then chilled on ice.  Reaction buffer, deoxynucleotides, RNasin® and 
MMLV RT were then added to give a final reaction mix of 50mM Tris-HCl, pH 8.3, 75mM KCl, 3mM MgCl2, 
10mM DTT, 40U RNasin, 0.8mM deoxyribonucleotides, 400U MMLV RT in a total volume of 25µl.   Io cDNA 
synthesis was performed at 37oC for 40 min, then at 42oC for 40 min. Reactions were heat  inactivated at 80oC for 10 
min. In each RT experiment, the following negative control reactions were routinely carried out: a) 1o cDNA 
reactions carried out in the absence of MMLV-RT; b) all RT  reagents excluding template RNA.  Aliquots (3.5µl) of 
each 1o cDNA were then used as templates in subsequent  PCR reactions (25µl ) using primers pairs selective for 
TPα or TPβ. 
 The general organization of Exon 2 - Intron 2 - Exon 3 of the human TP gene  corresponding to the region 
encoding the unique C-terminal cytoplasmic tails of TPα and TPβ are shown in Figure 1.   Oligonucleotide primers 
were designed to specifically amplify TPα and TPβ mRNA sequences in PCR reactions based on the published 
cDNA sequences of the placental TPα (28) and the endothelial TPβ (30). In all cases, the common Primer A with the 
sequence 5’GAGATGATGGCTCAGCTCCT3’  corresponding to nucleotides 724 -743 of Exon 2 was utilised as the 
5’ or Sense primer; whereas Primer C (5’CCAGCCCCTGAATCCTCA3’ ; nt 1123-1106 of TPα) was used as 
specific Antisense primer for TPα and Primer B (5’ AGACTCCGTCTGGGCCG3’; nt 1651 - 1643 plus 983 - 976, 
which correspomds to nt  992-976 of TPβ mRNA ) was used as specific antisense primer for TPβ.  An additional 
Primer D (5’TGGGCCACAGAGTGAGACTC3’; nt 1665-1646) was designed to co-amplify both TPα and TPβ 
sequences. These primers (Primers A-D) were designed to span across Intron 2 (4.3 kB) such that only PCR products 
derived from 1o cDNA would be amplified, thereby eliminating genomic artefacts. As an internal control for each 
experiment, oligonucleotides were also designed to direct PCR amplification of DNA from the constitutively active 
gene, glyceraldehyde-3-phosphate dehydrogenase (GA3PDH), namely Gf 5’TGAAGGTCGGAGTCAACG 3’ (nt 
71-89) and Gr 5’CATGTGGGCCATGAGGTC3’ (nt 1053-1035).  
 The random primed first strand (1o) cDNA was used as a template for the PCR amplification of TPα, TPβ, 
TPα plus TPβ and GA3PDH specific sequences.  In brief, aliquots (3.5 µl) of 1o cDNA were used as templates in 
each PCR reaction (25 µl)  in the presence of 10 mM Tris-Cl, pH 8.3., 50 mM KCl, 2 mM MgCl2, 0.2 mM dNTPs, 
6.7 % glycerol, 1 µM Sense primer, 1 µM Antisense  primer, 1 U Taq DNA polymerase. PCR amplifications were 
carried out using  the following repeat cycle conditions for 40 cycles:  (denaturation at 95 oC, 1 min; primer 
annealing at 50 oC,  30 sec; elongation at 72 oC for 3 min) followed by a single final extension reaction ( 95 oC, 1 
min; 50 oC,  30 sec; 72 oC for 10 min). In the case of primer pairs A/D, PCR reaction components were initially 
assembled without any Taq DNA polymerase and were pre-heated to 95 oC for 5 min, then cooled on ice for 1 min. 
Thereafter, Taq DNA polymerase was added and PCR amplifications were carried out using the following repeat 
cycle conditions for 40 cycles:  (95 oC, 1 min; 54 oC,  30 sec; 72 oC, 3 min) followed by a single final extension 
reaction (95 oC, 1 min; 54 oC,  30 sec; 72 oC, 10 min). In each PCR experiment the following negative control 
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reactions were routinely carried out for each primer pair: a) PCR  reactions carried out in the absence of  1o cDNA 
template; b) template DNA resulting from 1o cDNA reactions carried out in the absence of MMLV-RT; c) template 
DNA resulting from 1o cDNA reactions carried out in the absence of template RNA. 
 Following amplifications, products of the PCR reactions (7µl) were analysed by agarose gel electrophoresis 
(39); the gels were then subjected to densitometry by scanning on a UVP GDS800 gel documentation system. The 
levels of TPα and TPβ mRNA expression were determined by measurement of PCR product band intensities on the 
densitometric scans; in each case, expression levels, in arbitrary units, are represented as a ratio relative to GA3PDH 
expression (i.e TPα /GA3PDH ± standard error of the mean (S.E.M.); TPβ/GA3PDH ± S.E.M., in arbitrary units) and 
the relative levels of TPα to TPβ are represented as a ratio of these values in each case, i.e TPα/TPβ ± S.E.M., 
arbitrary units.  For each cell or tissue type screened, at least three independent experiments were carried out.  
Results are expressed as mean ± S.E.M. where n ≥ 3. For each independent cell / tissue type screened, the ratio of 
TPα / GA3PDH and TPβ / GA3PDH were analysed using the  unpaired Student t-test. P values of less than or equal 
to (≤ ) 0.05 were considered to indicate a statistically significant difference and, where values were found to be 
significant, are indicated in the Figures. 
 
Southern Blotting and Phosphor Image Analysis. 
Southern Blot analysis of PCR generated fragments was carried out using standard methodology essentially as 
described by Sambrook et al., 1989. 
Briefly, following agarose gel electrophoresis, PCR products were transferred to Duralon -UV nylon membrane 
(Stratagene) by upward capillary transfer (39). Aliquots (10 pmoles ) of the radiolabelled oligonucleotides Probe X 
(5’ CTGTCCCGCACCACGGAG 3’, corresponding to nucleotides 844-861 of the TPα and TPβ mRNA) or the 
Probe Gp (5’ CAGAAGACTGTGGATGGC 3’, corresponding to nucleotides 552-569 of the GA3PDH mRNA) 
were each 5’end labelled with 16 units of T4 polynucleotide kinase for 45 min at 37oC in a final reaction volume of 
25µl in the presence of 70mM Tris-Cl, pH 7.6, 10mM MgCl2, 5mM DTT and 20 pmoles [γ -32P] ATP 
(6000Ci/mmol; 10mCi/ml).  Carrier nucleic acid (55µg yeast tRNA) was added and phosphorylated oligonucleotide  
primers were co-precipitated with 0.1 volumes of 3M sodium acetate, pH 5.2 and 2.5 volumes of absolute ethanol at 
-20oC for 30 min. The resultant pellet was washed in 70% ethanol and dried in vacuo. The lyophilised pellet was 
then re-suspended in 20 µl dH2O and used as a probe for hybridization in the presence of 6x SSC, 0.5% SDS and 
100µg/ml denatured, sonicated  salmon sperm DNA overnight at 44oC.  Membranes were washed as previously 
described (39). Radioactive images were captured by autoradiography on Fuji New RX Film and quantified by 
Phosphor Image analysis using a  GS 250 Molecular Imager (BioRad).  
 
 
Cloning and sequencing  of TPα and TPβ  PCR generated fragments 
In order to confirm the absolute identity of the TPα and TPβ specific PCR products, generated using primer pairs A/C 
and A/B, respectively,  each product was subcloned into the vector pBluescript II SK(-) and then subjected to DNA 
sequence analysis.  To facilitate subsequent subcloning, PCR amplifications were carried out in the presence of 
oligonucleotide primers that had been 5’ phosphorylated using T4 polynucleotide kinase prior to the PCR reactions.  
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 Briefly, 500pmoles of the required oligonucleotide primers (A, C or B) were 5’ phosphorylated with 16 
units of T4 polynucleotide kinase in the presence of 50µM ATP, 10mM MgCl2, 70mM Tris-Cl., pH 7.6 in a final 
volume of 100µl. Reactions were incubated at 37oC for 90 min and were heat inactivated at 65oC for 10 min. Carrier 
nucleic acid (5.5µg yeast tRNA) was added and phosphorylated oligonucleotide primers were co-precipitated with 
0.1 volumes of 3M sodium acetate., pH 5.2 and 2.5 volumes of absolute ethanol at -20 oC for 30 min. The resultant 
pellet was washed in 70% ethanol and dried in vacuo. The lyophilised pellets were resuspended in 20µl distilled 
H2O. Aliquots (1.25µl) of each phosphorylated primer was used to direct PCR amplification of either TPα or the TPβ 
from 1o cDNA template as previously described. Following amplification, any recessed DNA ends were filled in by 
the addition of 10 units of DNA polymerase I Klenow fragment to each of the resulting 25µl PCR reactions and were 
further incubated at 30oC for 15 min. Thereafter, the Klenow treated PCR fragments  were subjected to 1.2% agarose 
gel electrophoresis and  the TPα  (400bp) and the TPβ (269bp) fragments were gel purified using the GeneClean II® 
kit. Phenol-chloroform extraction and precipitation of the gel purified PCR products was performed in the presence 
of 0.1 volumes of 3M sodium acetate, pH 5.2 and 2.5 volumes of absolute ethanol at -20oC. The washed pellet was 
resuspended in distilled H2O.    PCR fragments were then subcloned by blunt end ligation into the Sma I site of 
pBluescript II SK (-) using standard methodology (39).  Recombinant plasmids containing either the TPα or the TPβ 
specific PCR products  were sequenced using the Sequenase Version 2.0 DNA sequencing kit. 
 
Saturation Radioligand binding assay 
Cells were harvested by scraping, centrifuged at 500 x g at 4oC for 5 min and then washed three times in phosphate 
buffered saline (PBS). Protein concentrations were determined using the Bradford assay (40).  Cells were then 
harvested and were resuspended in HBSSHB (modified Ca2+/Mg2+-free Hanks’ buffered salt solution, containing 
10mM HEPES pH 7.67, 0.1% bovine serum albumin) at a final concentration of 1mg/ml. Saturation radioligand 
binding experiments with the TP antagonist [3H]SQ29,548 (20 nM, 50.4 Ci/mmol) were carried out at 30oC for 30 
min in 100µl reactions using approximately 100µg cell protein per assay. Non-specific binding was determined in the 
presence of excess nonlabeled SQ29,548 (10µM). Reactions were terminated by the addition of ice-cold 10mM Tris, 
pH 7.4 (4 ml) followed by filtration through Whatmann GF/C glass filters, and subsequent washing of the filters 3 
times with 4 ml 10mM Tris, pH 7.4, followed by liquid scintillation counting of the filters in 5ml of scintillation 
cocktail. Results were expressed as the fmol [3H]SQ29,548 incorporated per mg cell protein ± S.E.M, where n ≥ 4. 




In this study, we have developed a semi quantitative reverse transcriptase (RT)-PCR based approach to screen for 
and determine the relative expression of TPα and TPβ mRNA sequences in a variety of human cell and tissue types of 
relevance to TXA2 biology.  Where possible, in order to confirm actual TP protein expression, measurements of 
mRNA expression levels were complimented by radioligand binding studies using the selective radiolabelled TP 
antagonist [3H]SQ29,548. 
 Figure 1 outlines the general organisation of the human TP gene in the region where the differential splicing 
event giving rise to the two receptor isoforms occurs and the oligonucleotide primer pairs which were used in the 
RT-PCR reactions to amplify either TPα (Primers A/C; nucleotides 724 - 1123; 400bp) or  TPβ (Primers A/B; 
nucleotides 724 - 992 of TPβ mRNA; 269bp) specific sequences.  As a confirmatory PCR reaction, an additional 
primer pair was used to co-amplify  both TPα and TPβ (Primers A/D; nucleotides 724 - 1665 of TPα; 942bp and 
nucleotides 724 - 1006 of TPβ; 283 bp) specific sequences. In all cases, the 5’ and 3’ primers of the TPs were 
designed to flank the large 4.3kB Intron 2  thereby ensuring that the PCR products derived from 1o cDNA could 
readily be distinguished from those which might be generated from trace genomic DNA contamination of the RNA 
preparations. As an internal control for a constitutively transcribed gene, oligonucleotide primers (Primers Gf / Gr; 
nucleotides 71 - 1053; 983 bp) were also used to amplify GA3PDH mRNA sequences in each experiment.    
 A typical electrophoretogram of RT-PCR generated products from the platelet like human erythroleukemic 
(HEL) megakaryocyte cell line is presented in Figure 2A.  Clearly, TPα (Primer A/C, lane 2), TPβ (Primer A/B, lane 
1), TPα plus TPβ (Primer A/D, lane 9) as well as GA3PDH (Primer Gf/Gr; lane 3)  DNA fragments of the predicted 
sizes were specifically amplified in each case.  The amplified fragments were subsequently cloned into pBluescript II 
SK(-) vector and were confirmed to be correct by DNA sequence analysis (data not shown).  Whereas  HEL cells 
express both TPα and TPβ mRNA sequences at ratio’s of  0.87 ± 0.06 and 0.40 ± 0.008 relative to GA3PDH, 
respectively,  these cells express 2.32 ± 0.34 ( p ≤ 0.05) fold more TPα than TPβ mRNA (Figure 2B).  Consistent 
with previous data (32), TP expression in HEL cells was confirmed by  radioligand binding studies and were found 
to express 36.7  ± 6.52 fmol [3H]SQ29,548  / mg cell protein (Figure 2C).    
 Routinely, in order to validate data obtained from densitometric scans of ethidium bromide stained gels, 
PCR fragments were also screened by Southern Blot analysis using an internal 32P radiolabelled oligonucleotide 
Probe  X (Nucleotides  844 - 861 of  TPα and TPβ mRNA sequences) as specific TP cDNA probe and  radiolabelled 
oligonucleotide Probe Gp (Nucleotides 552 - 569 of  GA3PDH  mRNA)  as specific GA3PDH  cDNA probe.  
Southern blots containing the PCR generated cDNA fragments (primer pairs A vs C to ampify Tpα;  primers A vs B 
to amplify TPβ cDNA; Gf vs Gr to amplify GA3PDH cDNA) were screened by hybridization, using standard 
methodology.  Thereafter, the Southern Blots were subjected to autoradiography and densitometric scanning by 
Phosphor Image Analysis using a BioRad GS 250 Molecular Imager.   Results of a typical autoradiogram are 
presented in Figure 2D. In each case, data generated by Phosphor Image analyses of the Southern Blots were 
consistent with the data generated from the ethidium bromide stained gels. 
 
TP expression in uterine and vascular smooth muscle. 
The immortalised smooth muscle cells lines derived from adult aortic (ALTR), foetal aortic (VLTR) and uterine 
(ULTR) smooth muscle cells (SMC’s) have been previously described (38).  These cells were used as model cell 
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lines and using the RT-PCR approach, were each found to co-express both TPα and TPβ isoforms.  Specifically, 
foetal and adult SMC’s express comparable levels of TPα mRNA with  ratio’s of TPα / GA3PDH  were 0.90 ±  0.06 
and  0.81 ±  0.08, respectively (Figure 3A).  In contrast, there is greater expression of TPβ in foetal VSM compared 
to adult VSM, with ratio’s of TPβ / GA3PDH mRNA’s found to be 0.81  ±  0.14 and 0.36 ±  0.06, respectively.  
Hence, the adult aortic SMCs express 2.37 ± 0.43 fold more TPα than TPβ (Figure 3B, p ≤ 0.05) whereas foetal SMC 
express 1.16 ± 0.16 fold greater levels of TPα than TPβ.   
 Uterine SMCs express over 3-fold greater levels of TP
α
 relative to TPβ (Figure 3B, p ≤ 0.025). In contrast, 
uterine tissue, which comprises uterine SMC, fibroblasts and a number of other cell types, expresses similar, high 
levels of both TP isoforms (ratio TPα and TPβ mRNA’s relative to GA3PDH were 1.35 ± 0.36 and 1.22 ± 0.36, 
respectively). 
 Expression of TP in the immortalised foetal, adult and uterine smooth muscle cells were confirmed by 
radioligand binding studies (Figure 3C), however, as the radioligand [3H]SQ29,548 is not receptor isoform selective, 
no direct correlation between the level of isoform-specific TP protein and mRNA expression could be made. 
 
Analysis of TP expression in  HUVEC’s. 
Primary human umbilical vein endothelial cells (1o HUVECs) were confirmed to express TPβ mRNA, albeit at low 
levels (ratio of TPβ / GA3PDH was 0.07 ± 0.005; Figure 4A & 4B). In contrast however to previous reports 
(Raychowdhury et al., 1994), 1o HUVEC’s were also found to express TP
α
 mRNA (Figure 4A); in fact, these cells 
were found to express 5.8 fold greater levels of TP
α
 relative to TPβ (p ≤ 0.01; Figure 4B & C).  These data were also 
confirmed by Southern Blot followed by Phosphor Image analysis where the ratio of TPα / TPβ mRNA expression 
was found to  be 6.09 (Figure 4D).  Consistent with these findings, the spontaneously transformed HUVEC-derived 
cell line, ECV-304, was also found to express both TP isoforms, with greater levels of both TP
α
 and TPβ mRNA 
expression relative to 1o HUVECs (Figure 4B & 4C).  TP protein expression in the immortalised ECV-304 cells was 
also confirmed by  radioligand binding studies (13.9 ± 3.51 fmol / mg protein) . 
. 
Expression of TP in trophoblasts. 
Primary trophoblast cell lines were generated from four independent placental donors and were termed ED-27, ED-
31, ED-77 and Tm-1. Both TP isoforms are expressed at the mRNA level in the ED-27, ED-31, ED-77, and Tm-1 
trophoblast cell lines (Figure 5A- 5C). However, variations occur in the relative expression of the TP isoforms; TPα 
is expressed at approximately equivalent levels in all four cell lines (Figure 5B). Considerable differences in the 
expression of TPβ mRNA were found with lowest levels of TPβ being expressed in ED-27 (ratio of TPβ / GA3PDH 
was 0.23 ± 0.08), TPβ mRNA is most abundantly expressed in ED-77 and Tm-1 (ratio of TPβ / GA3PDH were 0.87 
± 0.08 and 0.87 ± 0.03, respectively).  Thus, TPα predominates in ED-27 and ED-31, with significantly greater levels 
of TPα relative to TPβ expressed in ED-27 cells (p  ≤ 0.005). No significant differences in the expression of TPα 
relative to TPβ were observed in ED-77 or Tm-1 cells. Radioligand binding studies confirmed protein expression and 
indicated similar clonal variation in TP expression levels (Figure 5D). 
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Expression of TP isoforms in brain tissue, small intestine and thymus. 
Foetal and adult brain tissue expressed both TP
α
 and TPβ mRNA with 2-fold greater expression of TPα relative to 
TPβ in both cases (ratio TPα /TPβ were 2.12 ± 0.25;  p ≤ 0.05 and 1.97 ± 0.33, p ≤ 0.05 for foetal and adult brain 
tissue, respectively). Hence, there were no significant differences in the level or relative expression of the TP 
isoforms in foetal brain tissue compared to adult brain tissue. 
  Human thymus and small intestine tissue were also found to express both TP
α
 and TPβ mRNAs.  
The TPα predominated in both tissues with greater levels of TPα relative to TPβ mRNA expressed in thymus (ratio 
TPα/TPβ was 3.31  ± 0.15, p ≤ 0.01) and small intestinal (ratio TPα/TPβ was  1.51  ± 0.12) tissue.  
 
Exclusive expression of TPα in a  hepatoblastoma cell line. 
Liver tissue express both TP
α
 and TPβ mRNAs with significantly (p ≤ 0.05) greater levels of TPα expressed relative 
to TPβ (ratio of TPα / GA3PDH was 0.78 ±  0.11; ratio of TPβ / GA3PDH was 0.29 ± 0.05; Figure 7B). However, in 
contrast to the tissue sample, the hepatoblastoma (Hep) G2 clonal cell line express TPα mRNA exclusively with no 
detectable expression of TPβ mRNA in these cells (Figure 7A -7C). Furthermore,  TPα is expressed at equivalent 
levels in both HepG2 cell and total liver (ratio of TPα / GA3PDH were 0.78 ±  0.11; ratio of TPα / GA3PDH were 
0.80 ± 0.09, in total liver and HepG2 cells, respectively; Figure 7C). TP protein expression in HepG2 cells was 
confirmed by saturation radioligand binding, with 44.4 ± 16.1 fmoles [3H]SQ,29548 bound/mg protein (Figure 7D).   




Prostanoids, autocoids synthesised mainly from membrane derived arachidonic acid, mediate diverse physiological 
and pathophysiological actions throughout the body.  Distinct G-protein coupled receptors (GPCRs) have been 
cloned for each of the primary prostanoids including receptors for TXA2 (TP, 23),  prostaglandin (PG) D2 (DP,41), 
PGE2 (EP1 - EP4,42-47), PGF2α (FP, 48) and PGI2 (IP, 49).  Among the large superfamily of GPCRs, the prostanoid 
receptors are somewhat unique in that receptor isoforms, derived from alternative mRNA splice variants, have now 
been cloned and identified for the EP3 (50, 51), the TP (30) and the FP (52) receptors.  In each case, the specific 
isoforms are identical thoughout their seven transmembrane domains but diverge exclusively within their C-terminal 
cytoplasmic tail regions.  The significance  of the existence of isoforms for prostanoid receptors is unclear, but in the 
case of EP3 isoforms, differences in receptor / G-protein coupling (50, 53 - 55) and receptor desensitization (56) have 
been found.  In the case of the TPα and TPβ isoforms, studies to date indicate that both receptors exhibit identical 
ligand binding profiles, identical coupling to phospholipase C but may oppositely regulate adenylyl cyclase activity 
(31, 37). In terms of receptor localization, PCR analyses indicated that HUVECs express TPβ mRNA only (30) and 
platelets express mRNAs for both TPα and TPβ isoforms (31). In view of the diverse actions attributed to TXA2 and 
its receptor, in both physiological and pathophysiological situations, it was considered imperative to investigate the 
distribution of TPα and TPβ in tissues of relevance to TXA2 biology, and indeed, pathophysiology.  Hence, in this 
study, we have developed a semi-quantitative RT-PCR approach to examine the relative expression of the individual 
TPα and TPβ isoforms.  In all, 17 different human cell / tissue types were examined, including 6  whole tissue 
samples and 5 primary cell lines.  In the absence of available tissue or primary cells, a number of representative 
immortalised cell lines were also examined including platelet-like megakaryocytes, adult and foetal aortic and uterine 
SMC’s, human umbilical vein endothelial cells and hepatoblastoma cell lines which may usefully reflect the relative 
expression of the TP isoforms in the progenitor tissues / cells.  
 Initially, vascular tissue and an erythroleukemia-like cell line were chosen for analysis since TXA2 is known 
to play a role in platelet aggregation (57), vascular smooth muscle mitogenesis (58) and contraction (59, 7). The 
mRNAs coding for both TP isoforms were identified in the platelet-like HEL 92.1.7 cell line. In addition, mRNAs 
for both TP isoforms were identified in vascular and uterine smooth muscle. However, greater levels of TPβ were 
found in foetal VSM relative to adult VSM, which may imply an age dependant down-regulation of TPβ mRNA 
expression in adult tissue, with no alteration of TPα expression.  
 Uterine tissue, which encompasses a milieu of cell types, including uterine SMC, blood vessels, stromal 
cells, endometrial glands and fibroblasts (60) was also found to express both TP isoforms.  A previous study 
reported the existence of a 2.8kb TP transcript in proliferative phase human uterus (60). In our study, uterine tissue 
expresses greater levels of both TP isoforms relative to that expressed by the uterine smooth muscle ULTR cell line 
which may indicate essential differences between uterine tissue and uterine derived smooth muscle cells.  However, 
there may, of course, be essential differences in TP expression between primary and immortalised smooth muscle 
cells which will require further investigation.  
 The endothelial TPβ has been so called since this novel spliced variant of TP was first cloned from 
HUVECs (30) which were reported to express TPβ exclusively with no detectable expression of TPα mRNA in these 
cells. However, in direct contrast to those studies reported by Raychowdhury et al (30), in the present study we 
found that whereas the endothelial TPβ was expressed, albeit at low levels in 1o HUVECs, TPα mRNA was also 
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identified in these cells. Furthermore, TPα mRNA levels far exceeded those of TPβ. The immortalised HUVEC-
derived cell line, ECV-304 was also found to express both TP isoforms, with expression of TPβ being greater in the 
immortalised cell line. TPα was also expressed at greater levels in the immortalised cell line when compared to the 1o 
HUVECs. 
 Trophoblasts mediate the transport of nutrients and immunoglobulins from the maternal to the foetal 
circulation and also functions as an endocrine organ (61). Recently, TXA synthase mRNA was identified in 
trophoblasts (62). In addition, serotonin-induced vasoconstriction in the human fetoplacental circulation appears to 
be mediated by TXA2 release and action (63). Increased fetoplacental resistance, a feature of pre-eclampsia, may be 
due, in part, to TXA2 as it is known to be a potent vasoconstrictor (59). Because of the role trophoblasts play in 
fetoplacental circulation, examination of TP isoform expression in trophoblast was undertaken.  Both TP isoforms 
were identified in all trophoblast cell lines; however, differences were observed in the relative expression of the 
mRNA’s for the individual isoforms.  Whereas TPα mRNA is expressed at approximately equivalent levels in all 4 
cell lines, up to 4 fold differences in the level of TPβ mRNA were observed. Corresponding differences in TP 
expression by the clonal trophoblast lines were observed in radioligand binding studies using the non-discriminatory 
TP antagonist SQ29,548 as a radioligand. The significance of the differential expression of TPα and TPβ in 
trophoblasts is currently unknown.  However, taking into account the inter-individual variation in endogenous 
mRNA and protein levels which were observed in trophoblast cell lines derived from normal individuals in this 
study, it is possible that the individual isoforms may have distinct roles to play in  pregnancy-induced hypertensive 
disorders including pre-eclampsia and pregnancy-induced hypertension.      
 TXA2 is thought to play a pathophysiological role in neuronal death during cerebral ischaemia (64). 
Previous studies have shown that the level of brain TXB2, the non-enzymatic degradation metabolite of TXA2, 
increases 55 fold in cerebral ischaemia, and has thus been implicated in post-ischaemic hypoperfusion and the 
development of cerebral injury after ischaemia (65). Using ligand based (SQ31,491) affinity chromatography, Borg 
et al, (66) identified two distinct TP receptors of 52kDa and 55kDa in rat brain. Recently, a TXA2 receptor was 
cloned from rat astrocytes (67) and was found to be 71.8% homologous to the human TPα cDNA. Interestingly, no 
alternatively spliced variant of the TP gene was identified in rat brain tissue (67). In this study, we identified both 
TPα and TPβ mRNAs in normal human foetal and adult brain tissue, with no age-related alterations in TP expression 
levels. TPα expression predominates in both adult and foetal brain tissue.  The significance of this is unclear but may 
point to TPα playing a greater role in mediating cerebral ischaemia. Our finding of TP expression at the mRNA level 
correlates with Blackman et al., (68) who reported the existence of functional TP protein in both rat neonatal 
oligodendrocytes and human oligodendroglioma cells by radioligand binding analysis and immunocytochemistry.    
 Northern blot analysis indicated that, in the mouse, TP mRNA is most abundantly expressed in thymic 
tissue (36). Additional studies indicated that the TP is most highly expressed in CD4-8- and CD4+8+ immature 
thymocytes, followed by CD4+8- and CD4-8+ cells (17). Previous studies have shown that the TXA2 agonist, STA2, 
induces apoptotic cell death in immature thymocytes and mediates thymocyte maturation and selection (17). 
Therefore, we examined thymic tissue for the presence of TPα and TPβ encoding mRNA’s. We found that both TP 
isoforms are expressed at the mRNA level in thymic tissue, with 3-fold greater expression of TPα relative to TPβ. 
The relative role of each TP isoform in DNA fragmentation and apoptosis remains to be determined. 
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 Northern blot analysis of various mouse organs revealed the presence of TP mRNA in thymus, spleen, lung, 
kidney, uterus, heart and brain tissue but not liver, stomach and ileum (36). In contrast, another study reported the 
existence of TP in endothelial cells, hepatocytes and Kupffer cells of rat liver, with an increase in TP mRNA 
expression observed with experimentally induced alcoholic liver disease in each of these cell types (69).   Moreover, 
Taniguchi et al., (70) reported that TXA2 antagonists may prove useful in the treatment of imflammatory bowel 
disorder implicating the importance of TP in intestinal tissue.  In view of these findings, we investigated the 
existence of mRNAs encoding the TP isoforms in human liver and small intestine tissue. Both TP isoforms were 
expressed in small intestine and liver tissue, with TPα expression predominating in both cases. Furthermore, RT-PCR 
analyses for TP mRNAs in the immortalised hepatoblastoma cell line, HepG2, revealed the expression of TPα 
exclusively with no detectable expression of TPβ mRNA.  The differential expression of TPα and TPβ mRNA’s in 
these cells clearly indicates that the 2 receptor isoforms are subject to distinct gene regulatory events in HepG2 cells, 
at least. 
 In conclusion, the TP is abundantly expressed at both the mRNA and protein level in tissues of relevance to 
TXA2 biology, such as erythroleukemia cells, vascular and uterine smooth muscle, uterus and placental tissue, 
endothelium, epithelium, trophoblasts, thymus, liver and small intestine with TPα expression predominated in most 
tissues examined. Whereas relative to GAP3DH mRNA,  TPα  is expressed at approximately equal levels in all cell / 
tissue types analysed (0.80 ± 0.04,  n = 47), considerable differences in TPβ   mRNA (0.49  ± 0.04,  n = 47) 
expression were observed. The apparent greater physiological requirement for TPα over TPβ remains to be studied in 
the future. In addition, the hepatoblastoma cell line, HepG2, exclusively expresses TPα, implicating a redundant 
physiological role for TPβ in this cell type.  Contrary to previous reports, HUVECs express both the TPα and 
TPβ mRNA’s with significantly greater levels of TPα than TPβ expressed.  Thus, it is evident from this study that 
mRNA’s for both isoforms are co-expressed in placental/platelet tissue, in endothelial cells and, indeed, in a number 
of other cell/tissue types.  This fact raises doubts as to whether the TPα should be referred to as the platelet/placental 
TP and the TPβ referred to as the endothelial receptor (30).  Our findings also suggest that the molecular mechanisms 
responsible for TPα and TPβ mRNA expression are subject to subtle regulation in different tissues and cell types.  
Further investigations are required to understand the molecular regulation in TPα and TPβ mRNA expression. 
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Figure 1. Organization of the h. TP gene. 
A.  The general organization of Exon 2 - Intron 2 - Exon 3 of the human TP gene  corresponding to the region 
encoding the unique C-terminal cytoplasmic tail of TPα and TPβ are shown.  Exon 3 spans nucleotides  811- 1029, 
encoding amino acid residues 271 - 343 of TPα, plus an additional 942 nucleotides (corresponding to nucleotides 
1029 -1971) of 3’ untranslated sequence (3’ UTR).  Nucleotides 984 - 1642 of the TPα coding sequences behave as a 
potential intron (Intron 2B) in the TPβ mRNA; splicing of nucleotides 983 / 1643 results in an mRNA which has a 
new open reading frame and encodes a protein of 407 amino acids, of which amino acids 328 - 427 are unique to the 
TPβ.  B. The following primer pair combinations were used in the PCR reactions: Primer pairs A/C specifically 
amplify TPα;  Primer pairs A/B specifically  amplify TPβ;  Primer pair A/D was used to co-amplify TPα and TPβ 
isoforms. C. Primer pairs Gf and Gr were used to amplify a 982 bp fragment of GA3PDH cDNA sequences. 
 






Figure 2. Analysis of TP expression in HEL cells.  
A.  Agarose gel electrophoresis of RT-PCR products (7 µl/lane) derived from megakaryocyte HEL 92.1.7 cell  1o 
cDNA template:  lane 1, TPβ, 269bp product versus primers A/B; lane 2, TPα, 400bp product versus primers A/C; 
lane 3, GA3PDH, 983 bp product versus primers Gf/Gr; lanes 4-6, negative control PCR reactions carried out in the 
absence of template 1o cDNA in the presence of primers A/B, A/C and Gf/Gr, respectively; lanes 7-8, negative 
control reactions resulting from 1o cDNA template generated in the absence of MMLV-RT or template RNA, 
respectively, versus primers A/B; lane 9, TPα and TPβ, 942 bp and 283 bp products, respectively, derived versus 
primer A/B. Lane M, pGEM DNA markers; only the 179 - 1,198 bp fragments are shown.  B.  In each case, levels 
of TPα, TPβ mRNA were each represented as a ratio relative to GA3PDH expression (i.e. TPα/GA3PDH ±  S.E.M. 
and TPβ/GA3PDH ±  S.E.M., arbitrary units). Expression of TPα relative to TPβ are represented as a ratio of these 
values (i.e. TPα /TPβ ± S.E.M, arbitrary units). Both TPα  and TPβ are expressed in HEL 92.1.7 with significantly 
greater levels of  TPα  expressed relative to TPβ (* p<0.05).  C. Radioligand binding data  are expressed as fmol 
[3H]SQ29,548 / mg cell protein ±  S.E.M. where n 4.  D.  Southern blot analysis of  TPβ , TPα  and GA3PDH 
specific RT-PCR products, generated using primers A/B, A/C and Gf/Gr , respectively, screened using the  [γ -32P]  
radiolabelled TP specific Probe X and  GA3PDH specific Probe Gp. 






Figure 3. Analysis of TP expression in vascular SMC and uterus. 
A.  Levels of TPα, TPβ
 
and GA3PDH mRNA expression in foetal aortic (VLTR), adult aortic (AALTR) and uterine 
(ULTR) smooth muscle (SM) cells, and uterine tissue, in arbitrary units, were each represented as a ratio relative to 
GA3PDH expression (i.e. TPα /GA3PDH ±  S.E.M. and TPβ /GA3PDH ±  S.E.M.). B. Expression of TPα relative to 
TPβ are represented as a ratio of these values (i.e. TPα / TPβ
 
± S.E.M, arbitrary units). Significantly greater levels of 
TPα  relative to TPβ mRNA is expressed in adult aortic (* p<0.05) and uterine (*p<0.025) SM cells.  C. Radioligand 
binding data  are expressed as fmol [3H]SQ29,548 / mg cell protein ±  S.E.M. where n 4.  
 






Figure 4. Analysis of TP expression in 1o HUVEC and ECV-304 cells 
A.  Agarose gel electrophoresis of RT-PCR products (7 µl/lane) derived from primary HUVEC cell  1o cDNA 
template:  lane 1, TPβ, 269bp product versus primers A/B; lane 2, TPα, 400bp product versus primers A/C; lane 3, 
GA3PDH, 982 bp product versus primers Gf/Gr; lanes 4-6, negative control PCR reactions carried out in the absence 
of template 1o cDNA in the presence of primers A/B, A/C and Gf/Gr, respectively; lanes 7-8, negative control 
reactions resulting from 1o cDNA template generated in the absence of MMLV-RT or template RNA, respectively, 
versus primers A/B.  Lane M, pGEM DNA markers; only the 179 - 1,198 bp fragments are shown. B. Levels of 
TPα, TPβ and GA3PDH mRNA expression in 1o HUVEC  and ECV-304 cell lines, arbitrary units, were each  
represented as a ratio relative to GA3PDH expression (i.e. TPα /GA3PDH ±  S.E.M. and TPβ /GA3PDH ±  S.E.M.). 
C. Expression of TPα relative to TPβ are represented as a ratio of these values (i.e. TPα / TPβ
 
± S.E.M, arbitrary 
units). The 1o HUVECs express significantly greater levels of  TPα relative to TPβ (* p<0.05). D.  Southern blot 
analysis of  TPβ , TPα  and GA3PDH specific RT-PCR products from 1o HUVEC mRNA, generated using primers 
A/B, A/C and Gf/Gr , respectively, screened using the [γ -32P]  radiolabelled  TP specific Probe X and  GA3PDH 
specific Probe Gp. 
 
   







Figure 5. Analysis of TP expression in 1o Trophoblasts 
A. Agarose gel electrophoresis of RT-PCR products (7 µl/lane) derived from primary ED-31 cell  1o cDNA 
template:  lane 1, TPβ, 269bp product versus primers A/B; lane 2, TPα, 400bp product versus primers A/C; lane 3, 
GA3PDH, 982 bp product versus primers Gf/Gr; lanes 4-6, negative control PCR reactions carried out in the absence 
of template 1o cDNA in the presence of primers A/B, A/C and Gf/Gr, respectively; lanes 7-8, negative control 
reactions resulting from 1o cDNA template generated in the absence of MMLV-RT or template RNA, respectively, 
versus primers A/B. Lane M, pGEM DNA markers; only the 126 - 1,198 bp fragments are shown.  B. Levels of 
TPα, TPβ
 
and GA3PDH mRNA expression in four individual clonal trophoblast cell lines, namely ED-27, ED-31, 
ED-77 and Tm-1, in arbitrary units, were each represented as a ratio relative to GA3PDH expression (i.e. TPα 
/GA3PDH ±  S.E.M. and TPβ /GA3PDH ±  S.E.M.). C. Expression of TPα relative to TPβ are represented as a ratio 
of these values (i.e. TPα / TPβ
 
± S.E.M, arbitrary units). Significantly greater levels of TPα relative to TPβ expressed 
in ED-27 cells (* p<0.005).  D. Radioligand binding data  are expressed as fmol [3H]SQ29,548 / mg cell protein ±  
S.E.M. where n 4.  







Figure 6. Analysis of TP expression in foetal and adult brain, thymus and small intestine. 
A.  Levels of TPα, TPβ and GA3PDH mRNA expression in foetal brain, adult brain, thymus and intestine, in 
arbitrary units, were each represented as a ratio relative to GA3PDH expression (i.e. TPα /GA3PDH ±  S.E.M. and 
TPβ /GA3PDH ±  S.E.M.). B. Expression of TPα relative to TPβ are represented as a ratio of these values (i.e. TPα / 
TPβ
 
± S.E.M, arbitrary units). Significantly greater levels of TPα relative to TPβ are expressed in foetal brain tissue 
(* p<0.05), thymus (*p<0.05) and small intestine. 
 







Figure 7. Analysis of TP expression in liver tissue and HepG2 cells 
A.  Agarose gel electrophoresis of RT-PCR products (7 µl/lane) derived from HepG2 cell  1o cDNA template:  lane 
1, TPβ, primers A/B; lane 2, TPα, 400bp product versus primers A/C; lane 3, GA3PDH, 982 bp product versus 
primers Gf/Gr; lanes 4-5, negative control PCR reactions carried out in the absence of template 1o cDNA in the 
presence of primers A/B and A/C. Lane M, pGEM DNA markers; only the 126 - 1,198 bp fragments are shown. 
Both the TPα and the GA3PDH products were amplified (lanes 2 & 3, respectively). However, TPβ specific product 
(268bp, lane 1) was not detected.  B. Levels of TPα, TPβ
 
and GA3PDH mRNA expression in liver and the HepG2 
cell line, in arbitrary units, were each represented as a ratio relative to GA3PDH expression (i.e. TPα /GA3PDH ±  
S.E.M. and TPβ /GA3PDH ±  S.E.M.). C. Expression of TPα relative to TPβ are represented as a ratio of these values 
(i.e. TPα / TPβ
 
± S.E.M, arbitrary units). Both TPα and TPβ are expressed in liver tissue with significantly greater 
levels of TPα expressed relative to TPβ (* p<0.05).  D. Radioligand binding data  are expressed as  fmol 
[3H]SQ29,548 / mg cell protein ±  S.E.M. where n 4. 
 
 
 
